Vertical transmission of human immunodeficiency virus type 1: Seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein

Journal of Infectious Diseases

Volumn 175, Issue 1, 1997, Pages 63-69

  Ugen, Kenneth E ^a   Srikantan, Vasantha ^b   Goedert, James J ^b   Nelson Jr , Robert P ^b   Williams, William V ^b   Weiner, David B ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; VERTICAL TRANSMISSION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 0031033018     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.1.63     Document Type: Article

References (24)

1. Douglas GC, King BF. Maternal-fetal transmission of human immunodeficiency virus: a review of possible routes and cellular mechanisms of infection. Clin Infect Dis 1992;15:678-91.
2. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1241-7.
3. Newell ML, Peckham CS. Risk factors for vertical transmission of HIV-1 and early markers of HIV-1 infection in children. AIDS 1993;7(suppl 1):S91-7.
4. Goedert JJ, Mendez H, Drummond J, et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet 1989;2:1351-4.
5. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA 1990;87:3445-9.
6. Rossi P, Moschese V, Broliden PA, et al. Presence of antibodies to HIV-1 gp120 env epitopes correlates with the uninfected status of the children born to seropositive mothers. Proc Natl Acad Sci USA 1989;86:8055-8.
7. Halsey NA, Markham R, Wahren B, Boulos R, Rossi P, Wigzell H. Lack of association between maternal antibodies to V3 loop peptides of gp120 and maternal-infant HIV-1 transmission. J Acquir Immune Defic Syndr 1992;5:153-7.
8. Jean-Pierre A, Mathews T, Coombs R, et al. Antibody to V3 loop peptides does not predict vertical transmission of HIV. In: Program and abstracts: VII International Conference on AIDS (Florence, Italy). Rome: Istituto Superiore di Sanità, 1991.
9. Parekh BS, Shaffer N, Pau CP, et al. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. AIDS 1991;5:1179-84.
10. Robertson CA, Mok JY, Froebel KS, et al. Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus. J Infect Dis 1992;166:704-9.
11. Shaffer N, Parkeh B, Pau C, et al. Maternal antibodies to V3 loop peptides of gp120 are not associated with lack of perinatal HIV-1 transmission. In: Program and abstracts: VII International Conference on AIDS (Florence, Italy). Rome: Istituto Superiore di Sanità, 1991.
12. Ugen KE, Goedert JJ, Boyer J, et al. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 1992;89:1923-30.
13. Goedert JJ, Dublin S. Perinatal transmission of HIV type 1: associations with maternal anti-HIV serological reactivity. AIDS Res Hum Retroviruses 1994;10:1125-34.
14. Carrow EW, Vujcic LK, Glass KB, et al. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses 1991;10:831-8.
15. LaRosa G, Davide JP, Weinhold K, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing domain. Science 1990; 249:932-5.
16. Neurath AR, Strick N, Lee ESY. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19 to 36 residue) synthetic peptides. J Gen Virol 1990;71:85-95.
17. Horal P, Svennerholm B, Jeansson S, Rymo L, Hall WW, Vahlne A. Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates. J Virol 1991;65:2718-23.
18. Norrby E, Putkonen P, Bottiger B, Utter G, Biberfeld G. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. AIDS Res Hum Retroviruses 1991;7:279-5.
19. Warren RQ, Wolf H, Shuler KR, et al. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. J Virol 1990; 64:486-92.
20. + cell levels. J Clin Immunol 1991;11:13-21.
21. Broliden PA, Gegerfelt A, Clapham P, et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992;89:461-5.
22. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates neutralizing immune responses against HIV-1. Proc Natl Acad Sci USA 1993;90:4156-60.
23. Srikantan V, Wang B, Satre MA, et al. Cloning and biological characterization of human single-chain Fv fragments that mediate neutralization of HIV-1. AIDS 1994;8:1525-32.
24. Montifiori DC, Robinson WE, Schiffman SS, Michell WM. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;6:231-5.